Latest filing published 14 Aug 2026 for Dianthus Therapeutics, Inc. /DE/, €236k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Adam M. Veness, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Dianthus Therapeutics, Inc. /DE/ and Acceleron Pharma Inc. We count 14 filings; the first trade dates from 7 June 2021 and the latest from 13 August 2026.
No open-market purchase appears, only 5 sales worth €1.9M. No amount is published for 2 filings, which the totals therefore leave out. The rest of the record consists of 2 share grants and 6 option exercises. In 2026 alone, the filings show no purchases and 5 sales.
The newest entry dates from 14 August 2026: an option exercise of €236k, in Dianthus Therapeutics, Inc. /DE/. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations